Intarcia Therapeutics, Inc.
http://www.intarcia.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intarcia Therapeutics, Inc.
Coronavirus Update: CureVac Joins mRNA Vaccines Competitors, Beijing In Lockdown Again
CureVac starts mRNA vaccine trial, Interprotein uses AI in drug discovery and South Korea's Chong Kun and Hanmi make clinical progress.
Finance Watch: Kymera Will Start Protein Degrader Clinical Trials With $102m VC Round
Private Company Edition: Kymera said it will take up to three programs into the clinic by next year. Also, three new life science funds recently launched, including a Gates Foundation-backed accelerator for COVID-19 treatments, and Cell Medica reemerges as Kuur with new funding for CAR-NKT therapies.
Removal Of ‘Legal’ And ‘Implicit’ Terms Cleared Way For ICH Q12 Guideline
Concerns about potential regional variation and ambiguous applicability subside with final revision of lifecycle management guideline; training preparations begin.
Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Medical Devices
- Implantable Devices
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- BioMedicines, Inc.
- PhaseGain Clinical Research, Inc.
- Phoundry Pharmaceuticals